Publikasi Scopus FKUI 2021 per tanggal 30 April 2021 (299 artikel)

Aggarwal B., Jones P.W., Yunus F., Lan L.T.T., Boonsawat W., Ismaila A., Ascioglu S.
23007797900;26121204500;57194486277;57222571511;35608231000;15127439100;57222578443;
Direct healthcare costs associated with management of asthma: comparison of two treatment regimens in Indonesia, Thailand and Vietnam
2021
Journal of Asthma
Regional Respiratory Medical Affairs, GSK, Singapore, Singapore; Global Specialty & Primary Care, GSK, Brentford, Middlesex, United Kingdom; Institute for Infection and Immunity, St George’s University of London, London, United Kingdom; Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Indonesia-Persahabatan National Respiratory Center Hospital, Jakarta, Indonesia; Faculty of Medicine, University of Medicine and Pharmacy, Ho Chi Minh City, Viet Nam; Division of Respiratory System, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; Value Evidence and Outcomes, GSK, Collegeville, PA, United States; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Clinical Sciences R&D, GSK, Singapore, Singapore
Aggarwal, B., Regional Respiratory Medical Affairs, GSK, Singapore, Singapore; Jones, P.W., Global Specialty & Primary Care, GSK, Brentford, Middlesex, United Kingdom, Institute for Infection and Immunity, St George’s University of London, London, United Kingdom; Yunus, F., Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Indonesia-Persahabatan National Respiratory Center Hospital, Jakarta, Indonesia; Lan, L.T.T., Faculty of Medicine, University of Medicine and Pharmacy, Ho Chi Minh City, Viet Nam; Boonsawat, W., Division of Respiratory System, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; Ismaila, A., Value Evidence and Outcomes, GSK, Collegeville, PA, United States, Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Ascioglu, S., Clinical Sciences R&D, GSK, Singapore, Singapore
Objective: Daily inhaled corticosteroid (ICS) and long-acting beta-2-agonist (LABA) combinations comprising either regular maintenance therapy with ICS/LABA plus as-needed short-acting beta-2-agonist (SABA) or ICS-formoterol combinations used as maintenance and reliever therapy (MART) are recommended for moderate asthma. This analysis compares the direct costs of twice-daily fluticasone propionate/salmeterol (FP/salm) and budesonide/formoterol MART in three Southeast Asian countries. Methods: A literature review identified three randomized trials in patients with asthma (≥ 12 years) comparing regular twice-daily FP/salm with as-needed SABA versus MART in moderate asthma: AHEAD (NCT00242775/17 countries/2309 patients), COMPASS (AstraZeneca study SD-039-0735/16 countries/3335 patients), and COSMOS (AstraZeneca study SD-039-0691/16 countries/2143 patients). Economic analyses, conducted from a healthcare sector perspective (medication costs + healthcare utilization costs), applied unit costs from countries where healthcare costs are publicly available: Indonesia, Thailand and Vietnam. Results are expressed in British pound sterling (GBP/patient/year). Results: Annual exacerbation rates were low and differences between treatment strategies were small (range, FP/salm: 0.31–0.38, MART: 0.24–0.25) although statistically significant in favor of MART. Total average (minimum-maximum) direct costs (in GBP/patient/year) across the three studies were £187 (£137–£284), £158 (£125–£190), and £151 (£141–£164) for those who used FP/salm, and £242 (£217–£267), £284 (£237–£340) and £266 (£224–£315) for MART in Indonesia, Thailand and Vietnam, respectively. On average, total direct costs/patient/year with FP/salm were 22.8%, 44.6% and 43.0% lower than with MART for Indonesia, Thailand and Vietnam, respectively. Conclusions: In the three countries evaluated, total treatment costs with regular twice-daily FP/salm were consistently lower than with budesonide/formoterol MART due to lower direct healthcare costs. © 2021 GlaxoSmithKline. Published with license by Taylor & Francis Group, LLC.
healthcare utilization; ICS/LABA; maintenance therapy; medication; Southeast Asia
Taylor and Francis Ltd.
02770903
Article
Q2
664
7368